Skip to content
MarketScale
‹ Back to IndustriesSciences

Identifying Lightning Damage on Pecan Trees: Tips from TreeNewal

Join ISA Certified Arborist Wes Rivers from TreeNewal as he examines the aftermath of lightning damage on a pecan tree. In this insightful video, Wes highlights the path taken by the lightning bolt through the tree, causing superheating of the water inside. The resulting vapor expansion creates visible damage to the tree. The tree’s survival…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Zach Werblo · Isa Certified ArboristLightning-struck TreesTree CareTree Mitigation
Share

Key takeaways

01

Join ISA Certified Arborist Wes Rivers from TreeNewal as he examines the aftermath of lightning damage on a pecan tree.

02

In this insightful video, Wes highlights the path taken by the lightning bolt through the tree, causing superheating of the water inside.

03

The resulting vapor expansion creates visible damage to the tree.

Join ISA Certified Arborist Wes Rivers from TreeNewal as he examines the aftermath of lightning damage on a pecan tree. In this insightful video, Wes highlights the path taken by the lightning bolt through the tree, causing superheating of the water inside. The resulting vapor expansion creates visible damage to the tree. The tree’s survival following a lightning strike is uncertain, but there are measures that can be taken to enhance its chances.

If you have a lightning-struck tree, TreeNewal is here to help. Transitioning from the initial statement, you can schedule a consultation with one of their ISA Certified Arborists online or by contacting their team. This way, you can get expert advice on assessing the impact and exploring options for tree recovery.

Furthermore, you can learn about the effects of lightning strikes on trees and how TreeNewal can assist you in evaluating and preventing lightning damage to trees. To gain more information, be sure to watch the video. Don’t wait; take proactive steps to preserve your tree’s health and vitality.

Discover these additional TreeNewal resources about lightning!

Interested in Dallas Tree Care Services? Get In Touch with a TreeNewal ISA Certified Arborist today.

Are you looking for a sustainable Dallas-Fort Worth tree care company that prioritizes the health and longevity of your North Texas trees and landscapes? Look no further than TreeNewal, your trusted partner in tree care.

Our team of ISA Certified Arborists is dedicated to providing comprehensive tree services that ensure the vitality of your trees. From maintaining and reviving newly planted and established trees to diagnosing and treating tree diseases, fungi, and pests, we have you covered. At TreeNewal, we specialize in providing proper tree diagnosis and offering tailored maintenance and treatment plans to keep your trees thriving. Our team of experts actively applies top-quality fertilizer and soil conditioning products to enhance tree health from the roots up.

At TreeNewal, we specialize in tree diagnosis, maintenance, and treatment plans to keep your trees thriving. Our experts use top-quality fertilizer and soil conditioning products to enhance tree health from the roots up.

We understand the harmful effects of improper planting practices, so we employ techniques like air spading, root collar excavation, and vertical mulching to improve tree longevity. Our goal is to create sustainable landscapes that last.

We also offer tree surveys and mitigation services to help homeowners, developers, and commercial clients meet local tree preservation requirements while preserving the natural beauty of their surroundings.

Call TreeNewal today to schedule a consultation with our knowledgeable team. Let us be your trusted partners in preserving the beauty and longevity of your trees.

About the author

Zach Werblo
Zach WerbloDirector, Platform, BMS CAT

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Zach Werblo
Zach Werblo

Director, Platform

BMS CAT

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512